



# Innovation in the Patient Journey: Optimizing Outcomes for PAH Patients

This presentation will provide the audience with the evidence for early identification of patients with Pulmonary Arterial Hypertension (PAH) including: evidence-based approaches to identifying PH in high risk groups and the role of exercise testing in patient evaluation.

## INVITATION

Thursday, April 7, 2022  
19:00 – 20:15 Local time  
Room: Carson Hall C



### Speaker

**John Granton, MD**

**University of Toronto, Toronto, ON**

Dr. John Granton is a Professor of Medicine in the Faculty of Medicine at the University of Toronto. He specializes in pulmonary hypertension and critical care. His research interests include pulmonary hypertension, pulmonary embolic disease, exercise physiology and heart-lung interactions. He is a past President of the Canadian Thoracic Society and the current Chair of the Long-term Planning Committee.



### Moderator

**Paul Hernandez, MDCM, FRCPC**

**Dalhousie University, Halifax, NS**

## Learning Objectives

At the end of this presentation, attendees will be able to:



Identify and screen high-risk patients for pulmonary hypertension;



Evaluate a patient with an elevation in right ventricular systolic pressure (RVSP) and identify those who might benefit from directed therapies; and



Integrate exercise testing into the evaluation of patients with suspected or confirmed pulmonary hypertension.

## CanMED Roles Addressed:

Collaborator, Communicator, Medical Expert, Professional, Scholar

SOCIÉTÉ  
CANADIENNE DE  
THORACOLOGIE



CANADIAN  
THORACIC  
SOCIETY

janssen

PHARMACEUTICAL COMPANIES OF  
Johnson & Johnson

EM-93650